TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

TME Pharma N.V.

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results.NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Jun '24
revenue			16.50K -	16.50K 0%							8.50K -	8.50K 0%
cost of revenue		34K -		32K -		30K -		62K -					66K -
gross profit		-34K -	16.50K 148.53%	-15.50K 193.94%		-30K -		-62K -			8.50K -	8.50K 0%	-66K 876.47%
selling and marketing expenses		528.50K -		843.50K -
general and administrative expenses	562.50K -	562.50K 0%	875.50K 55.64%	875.50K 0%	1.01M 15.02%		934 -				760K -	760K 0%
selling general and administrative expenses	562.50K -	1.09M 93.96%	875.50K 19.75%	1.72M 96.34%	1.01M 41.42%	1.98M 97.02%	934 99.95%	1.81M 193,261.88%			760K -	760K 0%	1.58M 107.50%
research and development expenses	2.45M -	4.91M 100%	2.88M 41.41%	5.75M 100%	2.86M 50.31%	5.71M 100%	1.22K 99.98%	2.43M 199,900%			668.50K -	668.50K 0%	1.10M 64.55%
other expenses
cost and expenses	3.36M -	6.03M 79.71%	3.86M 35.98%	7.50M 94.25%	5.13M 31.58%	7.73M 50.57%	2.36K 99.97%	4.30M 181,879.70%			793K -	793K 0%	2.74M 245.90%
operating expenses	3.36M -	6.00M 78.70%	3.86M 35.62%	7.47M 93.42%	5.13M 31.28%	7.70M 49.99%	2.36K 99.97%	4.24M 179,257.02%	1.82K 99.96%		793K -	793K 0%	2.68M 237.58%
interest expense						2.82M -		580K -					520K -
ebitda	-3.00M -	-6.00M 100%	-3.71M 38.22%	-7.47M 101.56%	-3.85M 48.47%	-7.70M 100%		-4.24M -	-1.35K 99.97%		-1.39M -	-1.39M 0%	-2.66M 91.93%
operating income	-3.02M -	-6.03M 100%	-3.71M 38.42%	-7.50M 101.94%	-3.86M 48.49%	-7.73M 100%	-2.14K 99.97%	-4.30M 200,646.62%	-1.39K 99.97%		-1.42M -	-1.42M 0%	-2.74M 93.17%
depreciation and amortization	17K -	34K 100%	8.83K 74.02%	32K 262.28%	15K 53.13%	30K 100%		62K -	39 99.94%		33K -	33K 0%	66K 100%
total other income expenses net	-364.50K -	-729K 100%	-131K 82.03%	-190K 45.04%	-1.30M 584.21%	-2.60M 100%	-256 99.99%	-496K 193,650%			-117.50K -	-117.50K 0%	-505K 329.79%
income before tax	-3.38M -	-6.76M 100%	-3.85M 43.12%	-7.69M 100%	-5.16M 32.86%	-10.33M 100%	-2.40K 99.98%	-4.80M 199,900%			-1.54M -	-1.54M 0%	-3.25M 111.25%
income tax expense			500 -	1K 100%	-500 150%	-1K 100%		7K -			1K -	1K 0%	15K 1,400%
net income	-3.38M -	-6.76M 100%	-3.85M 43.12%	-7.69M 100%	-5.16M 32.86%	-10.33M 100%	-2.40K 99.98%	-4.80M 199,900%	-1.83K 99.96%		-1.54M -	-1.54M 0%	-3.25M 111.11%
weighted average shs out	610K -	673.97K 10.49%	708K 5.05%	783.06K 10.60%	900K 14.93%	993.45K 10.38%	1.45K 99.85%	1.90M 130,960.26%	3.37K 99.82%		6.69M -	6.69M 0%	27.35M 308.90%
weighted average shs out dil	610.93K -	673.97K 10.32%	708.77K 5.16%	783.06K 10.48%	900.52K 15.00%	993.45K 10.32%		1.90M -			6.69M -	6.69M 0%	27.35M 308.91%
eps	-5.54 -	-10.03 81.05%	-5.43 45.86%	-9.82 80.85%	-5.74 41.55%	-10.40 81.18%	-1.65 84.13%	-2.52 52.73%	-0.54 78.57%	0 100%	-0.23 Infinity%	-0.23 0%	-0.12 47.83%
epsdiluted	-5.53 -	-10.03 81.37%	-5.43 45.86%	-9.82 80.85%	-5.73 41.65%	-10.40 81.50%	-1.65 84.13%	-2.52 52.73%	-0.54 78.57%	0 100%	-0.23 Infinity%	-0.23 0%	-0.12 47.83%

COM:TMEPHARMA

TME Pharma N.V.

Last Close

0.15

25/11 09:23

Market Cap

6.05M

Beta: -

Volume Today

744.63K

Avg: -

Preview